Company Growth (employees)
Adamas Pharmaceuticals was founded in 2002 and is headquartered in Emeryville, US
Key People at Adamas Pharmaceuticals
William Dawson
CFO
David Chernoff
Chief Medical Officer
David Mahoney
Director
Mary Jean Stempien
VP, Clinical Research
Adamas Pharmaceuticals Office Locations
Adamas Pharmaceuticals has an office in Emeryville
Emeryville, US (HQ)
750 1900 Powell St
Adamas Pharmaceuticals Data and Metrics
Adamas Pharmaceuticals Financial Metrics
Adamas Pharmaceuticals's revenue was reported to be $572 k in FY, 2016 which is a 70% decrease from the previous period.
USD
Revenue (FY, 2016) | 572 k |
Revenue growth (FY, 2015 - FY, 2016), % | (70%) |
Net income (FY, 2016) | (60.1 m) |
EBIT (FY, 2016) | (61 m) |
Market capitalization (27-Jun-2017) | 377.4 m |
Closing share price (27-Jun-2017) | 17.4 |
Cash (31-Dec-2016) | 23.7 m |
Adamas Pharmaceuticals's current market capitalization is $377.4 m.
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 55.8 m | 1.9 m | 572 k |
Revenue growth, % | (97%) | (70%) | |
R&D expense | 21.9 m | 35.9 m | 31.2 m |
General and administrative expense | 15.5 m | 23.5 m | |
Operating expense total | 37.3 m | 59.4 m | 61.6 m |
EBIT | 18.5 m | (57.4 m) | (61 m) |
EBIT margin, % | 33% | (2998%) | (10662%) |
Interest income | (917 k) | 363 k | 811 k |
Pre tax profit | 17.6 m | (57.1 m) | (60.2 m) |
Income tax expense | (7.4 m) | (5.3 m) | (115 k) |
Net Income | 10.2 m | (51.8 m) | (60.1 m) |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 61.4 m | 33.1 m | 23.7 m |
Accounts Receivable | 524 k | 1.3 m | 794 k |
Inventories | 645 k | 5.1 m | 2.5 m |
Current Assets | 123.5 m | 113.2 m | 117 m |
PP&E | 1.2 m | 2.4 m | 3.2 m |
Total Assets | 161.2 m | 128.7 m | 142.5 m |
Accounts Payable | 3.7 m | 3.1 m | 3.6 m |
Current Liabilities | 12.5 m | 11.8 m | 9.7 m |
Non-Current Liabilities | 749 k | 547 k | |
Total Liabilities | 12.6 m | 10.3 m | |
Additional Paid-in Capital | 157.6 m | 178.5 m | 254.6 m |
Retained Earnings | (10.3 m) | (62.2 m) | (122.2 m) |
Total Equity | 147.1 m | 116.2 m | 132.2 m |
Financial Leverage | 1.1 x | 1.1 x | 1.1 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | 10.2 m | (51.8 m) | (60.1 m) |
Depreciation and Amortization | 155 k | 435 k | 808 k |
Accounts Receivable | (395 k) | (760 k) | 490 k |
Inventories | (97.8 m) | (153.7 m) | 2.1 m |
Accounts Payable | 1.5 m | (788 k) | 502 k |
Cash From Operating Activities | (24.2 m) | (28.3 m) | (48.1 m) |
Purchases of PP&E | (1.3 m) | (1.4 m) | (1.6 m) |
Cash From Investing Activities | (97.4 m) | 8.1 m | (26.7 m) |
Cash From Financing Activities | 47 m | 10.8 m | 65.4 m |
Interest Paid | 279 k | 279 k | |
Income Taxes Paid | 341 k | 4.7 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.1 x |
